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Deﬁning Cases of Diabetic Nephropathy in Genetic
Association Studies?
The Experience With the ACE Insertion/Deletion
Polymorphism in 53 Studies Comprising 17,791 Subjects
Daniel P.K. Ng, Bee-Choo Tai, and Xiu-Li Lim
OBJECTIVE—A key consideration when setting up genetic
studies is the case deﬁnition. For diabetic nephropathy, the case
deﬁnition is typically based on the presence of albuminuria.
However, it has been long debated whether diabetic nephropathy
cases deﬁned in this way may have a high prevalence of
nondiabetic kidney disease, especially if diabetic retinopathy is
absent.
RESEARCH DESIGN AND METHODS—We performed a
meta-analysis of 53 studies comprising 17,791 subjects investi-
gating the angiotensin-I converting enzyme insertion/deletion
polymorphism, taking into account the requirement for diabetic
retinopathy in the case deﬁnition and assuming a random-effects
model.
RESULTS—No publication bias was observed. The overall
pooled odds ratio (OR) for all 53 studies was 0.78 (95% CI
0.70–0.87; P  0.001), which indicated a signiﬁcant protection
against diabetic nephropathy for genotype II compared with
carriage of the D-allele. The pooled OR for the 11 studies (n 
3,413) requiring diabetic retinopathy in the case deﬁnition was
0.68 (0.53–0.86; P  0.002), and this was not signiﬁcantly
different from the pooled OR of 0.81 (0.71–0.92; P  0.001)
obtained from the 42 remaining studies (n  14,378) (P  0.198).
This lack of any signiﬁcant effect of diabetic retinopathy was
reiterated in subgroup analyses based on the type of diabetes
present.
CONCLUSIONS—Stipulating the presence of diabetic retinop-
athy in the case deﬁnition of diabetic nephropathy did not appear
to confer tangible beneﬁts when detecting genetic associations.
Besides reducing sample sizes, this stipulation makes the inter-
pretation of genetic associations more difﬁcult due to the poten-
tial confounding presence of diabetic retinopathy. Diabetes 57:
2541–2546, 2008
D
espite pharmacological interventions, diabetic
nephropathy is the major cause of end-stage
renal disease in many developed countries (1).
The efﬁcacy of such interventions may be de-
pendent on patient genotypes, and epidemiological evi-
dence ﬁrmly supports a role for genetic susceptibility in
the development of diabetic nephropathy in both type 1
and type 2 diabetes (2). Identiﬁcation of the genes respon-
sible holds the promise for greater insight into the patho-
physiology of this debilitating complication and may
ultimately provide novel therapies for disease prevention
and intervention.
A key consideration when setting up genetic studies for
diabetic nephropathy is the case deﬁnition. Because dia-
betic nephropathy is rarely diagnosed using invasive kid-
ney biopsies, the case deﬁnition of this complication in
genetic studies is typically based on the presence of
albuminuria (3). However, applying this case deﬁnition, it
is plausible that there is a substantial number of subjects
who were classiﬁed as having diabetic nephropathy but
actually have nondiabetic kidney disease instead. This
misclassiﬁcation in genetic studies will be expected to
drive any true association toward the null. In an attempt to
circumvent this problem, certain investigators have pro-
posed that diabetic nephropathy cases should be required
to have diabetic retinopathy as well. The rationale for this
proposal is that several studies have suggested that albu-
minuria can be attributed with conﬁdence to diabetic
nephropathy if diabetic retinopathy is present (4).
The vital question remains whether the stipulation of
diabetic retinopathy does indeed facilitate the identiﬁca-
tion of susceptibility genes for diabetic nephropathy in
real-life association studies. To address this issue, we
performed a meta-analysis on the association between
diabetic nephropathy and the ACE insertion/deletion poly-
morphism (ACE I/D), taking diabetic retinopathy status
into account. This genetic marker is the most extensively
studied polymorphism to date for diabetic nephropathy; as
such, data from 53 studies comprising 17,791 subjects
were available for this meta-analysis.
RESEARCH DESIGN AND METHODS
We used a preexisting dataset based on 47 studies published from January
1994 through March 2004 that examined the association between ACE I/D and
diabetic nephropathy (3). This dataset was subsequently expanded in 2006 by
the addition of six later studies to a total of 53 studies comprising 17,791
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DIABETES, VOL. 57, SEPTEMBER 2008 2541subjects (5–10). Brieﬂy, studies were considered if they provided sufﬁcient
information for a comparison of the ACE I/D genotype distribution between
case and control subjects. Case subjects were type 1 or type 2 diabetic
subjects fulﬁlling the minimal criterion of microalbuminuria, whereas control
subjects were deﬁned predominantly on the basis of normoalbuminuria. Of
the 53 studies, 11 speciﬁcally required the concomitant presence of diabetic
retinopathy when deﬁning cases of diabetic nephropathy (Table 1).
Statistical analyses. Funnel plots of the effect estimate based on log-odds
ratio were plotted against its SE to evaluate the possibility of publication bias
(11). The magnitude of the genetic association between ACE I/D and diabetic
nephropathy was obtained by calculating the odds ratio (OR) and its associ-
ated 95% CI. A random effects model was used based on the assumption that
the studies represented a random sample from the larger population of such
studies, with each having its own underlying effect size. Under this model, it
TABLE 1
Summary of 53 studies on ACE I/D and diabetic neuropathy
Lead author Year
Diabetes
type
Case
deﬁnition
requires DR
Case subjects
with DR (%)
Control
deﬁnition
requires DR
Control
subjects
with DR (%)
Case
genotypes (n)
Control
genotypes (n)
DD ID II DD ID II
Doria 1994 Type 1 No 70.0 No 21.0 24 35 15 16 41 20
Powrie 1994 Type 1 No NA No NA 7 8 4 24 37 24
Dudley 1995 Type 2 No 22.1 No 19.0 47 85 31 70 148 49
Fujisawa 1995 Type 2 No NA No NA 7 23 24 6 12 17
Mizuiri 1995 Type 2 Yes 100.0 No NA 19 50 11 9 11 11
Panagiotopoulos 1995 Type 2 No NA No NA 15 25 10 42 44 29
Schmidt 1995 Type 1 No 74.6 No 63.9 52 38 24 55 55 23
Tarnow 1995 Type 1 Yes 100.0 No 65.0 63 95 40 67 77 46
Rabensteiner 1995 Type 1 No NA No NA 16 39 9 8 33 15
Chowdhury 1996 Type 1 Yes 100.0 No NA 78 124 40 55 79 32
Doi 1996 Type 2 No 93.9 No 69.4 29 85 50 12 56 56
Nakajima 1996 Type 2 No NA No NA 14 50 37 4 19 18
Oh 1996 Type 1 No 83.9 No 42.9 10 9 12 7 10 11
Ohno 1996 Type 2 No 58.2 No 37.7 15 38 26 5 15 33
Yoshida 1996 Type 2 Yes 100.0 No 48.0 19 28 25 7 46 43
Barnas 1997 Type 1 No 100.0 No 78.0 14 27 9 4 21 15
Hibberd 1997 Type 1 Yes 100.0 No 46.5 21 42 9 36 43 7
Jeffers 1997 Type 2 No NA No NA 23 20 7 139 218 102
Marre 1997 Type 1 Yes 100.0 Yes 100.0 119 168 50 48 69 40
Ringel 1997 Type 1 No 41.0 No 20.4 35 68 31 57 130 39
Ringel 1997 Type 2 No 35.4 No 15.0 44 84 33 35 69 36
Demurov 1997 Type 1 No NA No NA 24 29 3 24 32 20
Schmidt 1997 Type 2 No 64.7 No 35.3 121 129 61 131 154 62
Pfohl 1998 Type 1 No 87.0 No 87.0 17 15 8 15 18 7
Freire 1998 Type 1 No 38.0 No 10.0 33 32 12 34 45 10
Grzeszczak 1998 Type 2 No 48.9 No 39.2 129 230 103 73 118 63
Hanyu 1998 Type 2 Yes 100.0 Yes 100.0 4 13725 1 4
Huang 1998 Type 2 No NA No NA 11 16 2 20 25 9
Wu 1998 Type 2 No NA No NA 12 18 21 1 11 6
Bouhanick 1999 Type 1 No NA No NA 4 5 4 19 34 10
De Cosmo 1999 Type 1 Yes 100.0 No NA 73 79 23 65 53 18
Kuramoto 1999 Type 2 No 42.4 No 13.8 9 16 8 3 13 13
Miura 1999 Type 1 No 71.4 No 44.7 13 49 36 10 58 35
Vleming 1999 Type 1 No 100.0 No NA 39 24 16 26 34 22
Wong 1999 Type 2 No 96.0 No 30.0 7 30 43 12 40 36
Hsieh 2000 Type 2 No NA No NA 40 59 80 21 50 86
van Ittersum 2000 Type 1 No 71.0 No 28.2 13 33 23 49 86 53
Araz 2001 Type 2 No 70.0 No 31.7 34 64 18 43 57 23
Azar 2001 Type 1 No NA No NA 23 272172
Gohda 2001 Type 2 No NA No NA 85 222 229 31 92 89
Taniwaki 2001 Type 2 No 84.9 No 72.5 14 40 32 12 26 31
Viswanathan 2001 Type 2 Yes 100.0 No 0.0 24 45 17 5 8 10
Fradin 2002 Type 2 No 35.0 No 19.5 38 61 18 44 54 20
Lee 2002 Type 2 No NA No NA 40 137 117 39 170 208
Ha 2003 Type 2 Yes 100.0 No 39.4 43 62 35 9 57 33
Hadjadj 2003 Type 2 No 4.5 No 2.0 1119 1468 552 208 282 115
Okuno 2003 Type 2 No 50.0 No 26.3 3 8 1 5 12 21
Arzu Ergen 2004 Type 2 No 16.0 No 22.0 9 11 5 24 21 5
Degirmenci 2005 Type 2 No NA No NA 12 25 6 30 47 19
Shestakova 2005 Type 1 No NA No NA 13 35 15 12 30 24
Canani 2005 Type 2 Yes 100.0 No NA 126 181 66 181 308 120
Wang 2005 Type 2 No 77.9 No NA 19 43 36 128 496 559
Ng 2006 Type 2 No NA No NA 96 148 47 52 83 32
The ﬁrst 47 studies have been previously referenced (ref. 3). *Absence of diabetic retinopathy speciﬁcally required in control subjects of this
study. DR, diabetic retinopathy; NA, information on diabetic retinopathy not available.
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effect size. Because the random effects model takes into account the inter-
study heterogeneity, such as differences in study design and case deﬁnitions
for diabetic nephropathy, it provides a more conservative evaluation of the
signiﬁcance of the association than one based on ﬁxed effects (12).
RESULTS
A total of 53 studies (n  9,556 case and 8,235 control
subjects) fulﬁlled the criteria for inclusion in this review
(Table 1). Twenty-one studies involved type 1 diabetic
subjects (n  4,154), while the remaining 32 studies were
conducted on patients with type 2 diabetes (n  13,637).
The potential presence of publication bias was assessed
using funnel plots of the estimate of log-odds ratio for the
genotype II versus DD/ID against its SE (Fig. 1A). Consid-
erable scatter was observed around the pooled log-odds
ratio estimate when the reciprocal of the SE was small and
approached convergence to form a symmetrical funnel, as
this reciprocal increased when all 53 studies were as-
sessed. Similarly, there was no evidence of such bias when
the 53 studies were analyzed separately, depending on
whether they required the concomitant diabetic retinopa-
thy in the case deﬁnitions (Fig. 1B and 1C).
The overall pooled OR for all 53 studies was 0.78 (95% CI
0.70–0.87; P  0.001), which indicated a signiﬁcant pro-
tection against diabetic nephropathy for genotype II com-
pared with carriage of the D-allele (Fig. 2). The pooled OR
for the 11 studies (n  3,413) requiring diabetic retinop-
athy in the case deﬁnition was 0.68 (0.53–0.86; P 
0.002), and this was not signiﬁcantly different from the
pooled OR of 0.81 (0.71–0.92; P  0.001) obtained from
the 42 remaining studies (n  14,378) that eschewed the
corroborative presence of diabetic retinopathy (P 
0.198) (Fig. 2).
In subgroup analyses on 21 studies conducted on 4,154
type 1 diabetic patients, the overall pooled OR was 0.84
(95% CI 0.68–1.05; P  0.119). The pooled OR for ﬁve
studies (n  1,759) requiring diabetic retinopathy status in
case subjects was 0.78 (0.58–1.06; P  0.110), and this was
similar to the pooled OR of 0.85 (0.63–1.13; P  0.255) for
the remaining 16 type 1 diabetes studies (n  2,395) (P 
0.704). In corresponding subgroup analyses, the overall
pooled OR was 0.75 (0.66–0.86; P  0.001) for the 32
studies comprising 13,637 type 2 diabetic patients. The
pooled OR for six studies (n  1,654) requiring diabetic
retinopathy in the case deﬁnitions was 0.54 (0.36–0.82;
P  0.004), which was not signiﬁcantly smaller than the
pooled OR of 0.79 (0.69–0.91; P  0.001) for the 26
remaining type 2 diabetes studies (n  11,983) (P  0.087).
We considered the possibility that this lack of effect of
diabetic retinopathy may be due to the fact that case
subjects in some studies may have had a high prevalence
of this complication even though it was not explicitly
required in the case deﬁnition. Because these studies
would have been placed under the category of studies not
requiring diabetic retinopathy in the preceding analyses,
the anticipated outcome would have been to drive any
apparent effect of diabetic retinopathy toward the null. To
clarify this issue, we scrutinized the published reports and
found that of the 42 studies that did not speciﬁcally
stipulate diabetic retinopathy in the case deﬁnition, 25 did
provide sufﬁcient clinical information for us to determine
the prevalence of diabetic retinopathy among the case
subjects (Table 1). Seven studies, in which diabetic reti-
nopathy was present in at least a majority (80%) of cases,
were selected from among these (Table 1). These studies
were combined with the 11 studies that speciﬁed diabetic
retinopathy in their case deﬁnitions for comparison with
the other remaining studies. The overall pooled ORs for
these 18 studies (n  4,414) was 0.71 (95% CI 0.58–0.87;
P  0.001) compared with 0.82 (0.72–0.94; P  0.003) for
the 35 remaining studies (n  13,377) (P  0.249) (online
appendix supplementary Fig. 1 available at http://dx.doi.
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FIG. 1. Funnel plot for the evaluation of publication bias in studies
of association of ACE I/D for all 53 studies (A), 42 studies not
requiring retinopathy in the case deﬁnition (B), and 11 studies
requiring diabetic retinopathy to corroborate the presence of dia-
betic nephropathy (C). DR, diabetic retinopathy.
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DIABETES, VOL. 57, SEPTEMBER 2008 2543org/10.2337/db08-0581]). Conﬁning our analyses to just the
36 studies that provided information about diabetic reti-
nopathy also yielded similar ﬁndings (data not shown). No
signiﬁcant differences associated with the requirement for
diabetic retinopathy were observed in either patients with
type 1 (P  0.448) or type 2 diabetes (P  0.236).
DISCUSSION
The promise of new insights into the pathogenesis of
diabetic nephropathy is fuelling intense efforts to identify
genes conferring risk of the complication (13–15). While
much of the attention has been placed on attaining large
sample sizes to provide power for detecting small effects,
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FIG. 2. OR and the associated 95% CI comparing ACE II with ID/DD genotypes in all 53 studies, which comprised 42 studies not requiring
diabetic retinopathy in the case deﬁnition and 11 studies requiring diabetic retinopathy (DR).
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nephropathy. In this study, we reviewed the literature on
the association of ACE I/D and diabetic nephropathy and
found evidence suggesting that stipulating the concomi-
tant presence of diabetic retinopathy in order to corrob-
orate a diagnosis of diabetic nephropathy is unlikely to
yield signiﬁcant beneﬁts when searching for genetic
associations.
The inclusion of diabetic retinopathy in the case deﬁni-
tion is commonplace in the published literature on ACE
I/D. Of the 53 studies, 21% imposed this requirement, and
this was comparable in studies focusing on either type 1 or
type 2 diabetic patients (24 and 19% respectively). This
practice is likely based on several studies that found that
only a subset of patients with proteinuria and/or azotemia
have kidney biopsies that substantiated a diagnosis of
diabetic glomerulopathy, which has subsequently been
taken to mean that proteinuria per se is insufﬁcient as
conclusive evidence of diabetic nephropathy (16–20).
However, in a systematic review of nine published reports
and their data (21), Oslen and Mogensen deliberated on
this issue and proposed that a very likely reason for the
high prevalence of nondiabetic kidney disease was the fact
that most of the reports were based on biased groups of
patients who were inadvertently selected for such nondi-
abetic kidney conditions (21). Another potential explana-
tory factor was the application of a differing criterion for
diagnosing glomerulonephritis, a major contributor to
nondiabetic kidney disease (21).
In our literature review, several points emerged that
should be highlighted. Of the 11 studies that required
diabetic retinopathy in the case deﬁnition, 9 studies did
not require that their control subjects have diabetic reti-
nopathy as well. It was also striking that one study
speciﬁcally required that its control subjects be free of
diabetic retinopathy when all its case subjects had this eye
complication (Table 1). Understandably, one would be
hard pressed to determine whether any observed associa-
tion between ACE I/D and diabetic nephropathy, diabetic
retinopathy, or even a combination of both complications
truly exists.
In practical terms, the requirement for diabetic retinop-
athy in control subjects will inadvertently diminish the
overall size of the study population, which is already
limited by the requirement that case subjects have diabetic
retinopathy. Unfortunately, on the basis of our present
results, this drop in sample size and consequent drop in
power come without any tangible reciprocal beneﬁt that
would be expected if disease misclassiﬁcation among
cases had been rampant in the absence of diabetic reti-
nopathy as previously suggested (20). Moreover, because
recent studies suggested that the majority (70–74%) of
albuminuric type 2 diabetic patients do indeed have dia-
betic glomerulopathy even in the absence of diabetic
retinopathy (22,23), it becomes questionable whether ge-
netic associations found in studies using diabetic retinop-
athy can be readily extrapolated to these diabetic
nephropathy patients. Nevertheless, it is noteworthy that
the overall pooled OR was slightly but consistently higher
in studies where diabetic retinopathy was prevalent, al-
though even with the large dataset under review, this
difference failed to reach statistical signiﬁcance. One may
thus consider the possibility that including diabetic reti-
nopathy helps in the identiﬁcation of potential genetic
factors for common underlying traits that may manifest as
a joint retinal-renal phenotype.
Several strengths and limitations of our study should be
discussed. On a positive note, the meta-analysis was
conducted on a substantial dataset comprising 17,791
patients from 53 studies. Moreover, there was no overt
sign of publication bias that would argue against the
validity of our results, with funnel plot analyses indicating
that small studies with negative ﬁndings were as likely to
be published as large studies with positive ﬁndings. In
addition, we performed subgroup analyses according to
whether the patients had type 1 or type 2 diabetes. This
distinction was relevant because of the debate as to
whether nondiabetic kidney disease is more common in
albuminuric patients with type 1 or type 2 diabetes (16,24).
A main limitation is that our study was restricted to ACE
I/D. This decision was borne of necessity because ACE I/D
is the most extensively studied polymorphism to date with
regards to diabetic nephropathy, and there is a severe lack
of extensive studies into other genetic markers. Despite
this situation, our study manages to render a ﬁrst critical
insight into the issue. Finally, reports of late have provided
evidence that diabetic nephropathy may be associated
with speciﬁc risk haplotypes at the ACE locus. However, a
meta-analysis on ACE haplotypes is precluded due to a
paucity of such reports (10,25).
In conclusion, our study using real-life association data
suggests that the presence of diabetic retinopathy may be
of limited practical value for deﬁning cases of diabetic
nephropathy when seeking genetic associations. In addi-
tion, the reduced sample sizes arising from such a stipu-
lation may make it harder to detect these associations.
Interpretation of the results from such studies could also
be hampered by the possible confounding presence of
diabetic retinopathy if left uncontrolled.
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